Company profile: Reprieve Cardiovascular
1.1 - Company Overview
Company description
- Provider of personalized decongestion and automated fluid management for acute decompensated heart failure, offering the Reprieve System, Personalized Volume Management System, and Guided Diuretic Therapy to tailor diuretic dosing, speed fluid removal and symptom relief, prevent hypotension, maintain renal function, and reduce readmissions; also conducting the FASTR trial comparing Reprieve therapy to optimized diuretics.
Products and services
- Guided Diuretic Therapy: A guided diuretic-therapy approach that manages fluids during treatment for acute decompensated heart failure, enabling precise and predictable fluid-level control to improve diuretic efficiency and patient outcomes
- Personalized Volume Management System: An automated volume-management platform that tailors diuretic dosing to accelerate fluid removal and symptom relief while preventing hypotension and maintaining renal function in acute decompensated heart failure
- Reprieve System: A personalized fluid-management system that architects decongestion for acute decompensated heart failure, safely removing excess volume to improve patient outcomes and prevent hospital readmissions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Reprieve Cardiovascular
EpiEP
HQ: United States
Website
- Description: Provider of pressure-guided access solutions for epicardial procedures, featuring the EpiAccess System for real-time guidance to the pericardial space via a needle with a fiber optic pressure sensor; the single-use EpiAccess Needle for precise tip location with real-time pressure data; and a compact Control Unit that captures and displays pressure data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EpiEP company profile →
CoreMap
HQ: United States
Website
- Description: Provider of advanced diagnostic technology for electrophysiologists and patients, offering CoreMap Ultra-High Resolution Electrodes to map atrial tissue electrical properties with high spatial resolution and aid identification of AF drivers, and Tissue Property Mapping to sequentially map tissue electrical properties, overcoming limitations of activation mapping.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoreMap company profile →
Endosense
HQ: Switzerland
Website
- Description: Provider of medical technology to improve the efficacy, safety and reproducibility of catheter ablation for treating cardiac arrhythmias, including TactiCath, the first and only force-sensing ablation catheter that gives physicians a real-time, objective measure of contact force; CE marked in May 2009.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endosense company profile →
CinCor Pharma
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on cardiovascular, metabolic, and kidney diseases, advancing promising clinical candidates toward marketing approval, including CIN-107, a novel aldosterone synthase inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CinCor Pharma company profile →
Acron Genomics
HQ: United Kingdom
Website
- Description: Provider of novel biotechnology platform development and commercialization in the life sciences, and of the introduction and development of promising new pharmaceutical compounds. U.S. publicly traded (OTC Markets/AGNM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acron Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Reprieve Cardiovascular
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Reprieve Cardiovascular
2.2 - Growth funds investing in similar companies to Reprieve Cardiovascular
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Reprieve Cardiovascular
4.2 - Public trading comparable groups for Reprieve Cardiovascular
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →